<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03067194</url>
  </required_header>
  <id_info>
    <org_study_id>266HOA16008</org_study_id>
    <nct_id>NCT03067194</nct_id>
  </id_info>
  <brief_title>The Study to Evaluate Efficacy and Safety of Celecoxib Capsule in Hand Osteoarthritis Patients</brief_title>
  <official_title>Open-label, Multicenter, Randomized Study to Assess the Efficacy and Safety of Celecoxib 200mg Capsule QD and Celecoxib 100mg BID in Hand Osteoarthritis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of Celecoxib capsule in hand&#xD;
      osteoarthritis patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a six-weeks, open-label, multi-center, randomized study. Patients take Celecoxib&#xD;
      200mg capsule once a day or Celecoxib 100mg capsules twice per day. If patients do not&#xD;
      tolerate the pain, they are able to take Acetaminophen as a rescue medication during 6 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 27, 2016</start_date>
  <completion_date type="Actual">November 20, 2018</completion_date>
  <primary_completion_date type="Actual">July 10, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of 100mm Pain VAS score at 6 weeks relative to the baseline value of each group</measure>
    <time_frame>baseline, 6weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in each item of K-AUSCAN at 6 weeks relative to the baseline value of each group</measure>
    <time_frame>baseline, 6weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total point change of K-AUSCAN at 6 weeks relative to the baseline value of each group</measure>
    <time_frame>baseline, 6weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total score change of insomnia severity at 6 weeks relative to the baseline value of each group</measure>
    <time_frame>baseline, 6weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dosing days of acetaminophen for 6 weeks in each group</measure>
    <time_frame>6weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total dose of acetaminophen for 6 weeks in each group</measure>
    <time_frame>6weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects using acetaminophen for 6 weeks in each group</measure>
    <time_frame>6weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety assessed by the incidence of adverse event</measure>
    <time_frame>up to 6weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>laboratory test(Hematology test, Blood chemistry test, Urinalysis)</measure>
    <time_frame>up to 6weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Osteoarthritis Hand</condition>
  <arm_group>
    <arm_group_label>Celecoxib 100mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib 200mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Celecoxib 200mg, Oral, QD(once daily), During 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib 100 MG</intervention_name>
    <description>Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks</description>
    <arm_group_label>Celecoxib 100mg</arm_group_label>
    <other_name>Celecoxib 100mg capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib 200mg</intervention_name>
    <description>Celecoxib 200mg, Oral, QD(once daily), During 6 weeks</description>
    <arm_group_label>Celecoxib 200mg</arm_group_label>
    <other_name>Celecoxib 200mg capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Agreement with written informed consent and 19 years of age and older&#xD;
&#xD;
          -  Patients history of OA of hand according to ACR criteria&#xD;
&#xD;
          -  The 100mm Pain VAS is over 40mm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of OA of hand surgery&#xD;
&#xD;
          -  Intra-articular injections within 3 months&#xD;
&#xD;
          -  History of OA of hand infections within 3 months&#xD;
&#xD;
          -  Who had taken a drug that has a control of result in clinical trial by investigator's&#xD;
             decision&#xD;
&#xD;
          -  Pregnant women, nursing mothers or Fertile women who not practice contraception with&#xD;
             appropriate methods&#xD;
&#xD;
          -  clinically significant hepatic, renal, cardiovascular diseases&#xD;
&#xD;
          -  Any history of adverse reaction to the study drugs&#xD;
&#xD;
          -  Patients with gastrointestinal ulcers or bleeding disorders&#xD;
&#xD;
          -  Finger joint injury within 6 months&#xD;
&#xD;
          -  Who had following results after examination&#xD;
&#xD;
               1. K ≥ 5.5mEq/L&#xD;
&#xD;
               2. eGFR ≤ 30ml/min/1.73m^2&#xD;
&#xD;
          -  Patients on any other clinical trial or experimental treatment in the past 3 months&#xD;
&#xD;
          -  Taking narcotic analgesics or patches&#xD;
&#xD;
          -  History of drug abuse or alcoholism&#xD;
&#xD;
          -  Who has Galactose intolerance, LAPP lactose intolerance, glucose-galactose&#xD;
             malabsorption or genetic disorders&#xD;
&#xD;
          -  An impossible one who participates in clinical trial by investigator's decision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyun Sook Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soonchunhyang University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chan Hong Jeon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soonchunhyang University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sung Hae Jang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soonchunhyang University Cheonan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>February 3, 2017</study_first_submitted>
  <study_first_submitted_qc>February 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis Hand</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

